CCL4 and inflammatory bowel disease: After accounting for multiple comparisons, each SD higher circulating MIP1b (CCL4) level was associated with a higher risk of IBD (NSNP = 4; ORIVW 1.14; 95% CI 1.07–1.21; pIVW = 2.4 × 10−5), but lower risk of RA (NSNP = 4; ORIVW 0.84; 95% CI 0.79–0.90; pIVW = 9.4 × 10−8).